GCGR

Glucagon Receptor

GCGR

Related Products

GCGR (glucagon receptor) is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

GCGR Related Products (146)
Recombinant Proteins (4)
Antibodies (3)

By Effects:	Inhibitors (7) Agonists (76) Antagonists (26) Modulators (8)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-114118

Semaglutide	Agonist	99.84%
Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.

HY-13443

Exendin-4	Agonist	99.94%
Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

HY-P0014

Liraglutide	Agonist	99.85%
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P0082

Glucagon (1-29), bovine, human		99.84%
Glucagon (1-29), bovine, human, porcine is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis. Glucagon (1-29), bovine, human, porcine activates HNF4α and increases HNF4α phosphorylation.

HY-P3506

Retatrutide	Agonist	99.95%
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.

HY-114118F

Semaglutide, FITC labeled	Agonist
Semaglutide, FITC labeled is a FITC labeled Semaglutide. Semaglutide, a long-acting GLP-1 alogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.

HY-116854

NNC 92-1687	Antagonist	98.74%
NNC 92-1687 is a non-peptide competitive human glucagon receptor antagonist (IC₅₀=20 μM; K_i=9.1 μM). NNC 92-1687 can be used in the research of type 2 diabetes.

HY-114118B

Semaglutide acetate	Agonist
Semaglutide acetate, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide acetate has the potential for type 2 diabetes treatment.

HY-P0264

Exendin(9-39) amide	Antagonist	99.81%
Avexitide (Exendin (9-39)) is a specific and competitive GLP-1 receptor antagonist.

HY-P0055

GLP-1(7-37)		99.82%
GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

HY-112185

Orforglipron	Agonist	99.80%
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete.

HY-P0054

GLP-1(7-36), amide acetate		99.36%
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-125824

Danuglipron	Agonist	98.63%
Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research.

HY-114118A

Semaglutide TFA	Agonist	99.92%
Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.

HY-50663

MK 0893	Antagonist	99.86%
MK 0893 is a potent and selective glucagon receptor antagonist with an IC₅₀ of 6.6 nM.

HY-103546

BETP	Agonist	99.35%
BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC₅₀s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively.

HY-121835

GLP-1R agonist 2	Agonist	99.94%
GLP-1R agonist 2 (compound 2) is an effective GLP-1R agonist that exerts its activating effect by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues of GLP-1R. GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity.

HY-P4146

Survodutide	Agonist	99.98%
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.

HY-19904

Adomeglivant	Antagonist	99.63%
Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus.

HY-P0055A

GLP-1(7-37) acetate		99.63%
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

Name
Email *

	Sorry, but the email address you supplied was invalid.

GCGR

GCGR

GCGR Related Products (146)

Recombinant Proteins (4)

Antibodies (3)

GCGR Related Products (146):